Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa.

Abstract excerpt

BACKGROUND: Ceftazidime-avibactam (CZA), ceftolozane-tazobactam (CT), and imipenem-relebactam (IMR) are newer β-lactam/β-lactamase inhibitor (BL/BLI) combinations used for treatment of multidrug resistant (MDR) Pseudomonas aeruginosa, although resistance has already emerged. Optimal use of these agents relies on timely, accurate susceptibility testing results and understanding of local resistance mechanisms....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Azabicyclo Compounds
• Share to beta-Lactamase Inhibitors